Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab, Anlotinib, and Gemcitabine for Metastatic Nasopharyngeal Carcinoma
NCT06886347Phase 1Recruiting
- Start
- Jul 2023
- Primary completion
- Apr 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of penpulimab and anlotinib in nasopharyngeal carcinoma (NPC). Primary endpoint: Progression-Free Survival at 2 years. Started Jul 2023; status: recruiting.
02
Drugs
penpulimabanlotinib
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06886347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06886347.